Evaluating ΔMTV%, ΔDmax%, and %ΔSUVmax of 18F-FDG PET/CT for mid-treatment efficacy and prognosis in diffuse large B-cell lymphoma.

IF 2.8 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Yali Cui, Yao Li, Wenhao Hu, Zhifang Wu, Sijin Li, Hongliang Wang
{"title":"Evaluating ΔMTV%, ΔD<sub>max</sub>%, and %ΔSUV<sub>max</sub> of <sup>18</sup>F-FDG PET/CT for mid-treatment efficacy and prognosis in diffuse large B-cell lymphoma.","authors":"Yali Cui, Yao Li, Wenhao Hu, Zhifang Wu, Sijin Li, Hongliang Wang","doi":"10.1007/s12672-025-02126-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the value of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in interim therapeutic and prognostic evaluation of patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Materials and methods: </strong>Data of 86 patients with pathologically confirmed DLBCL who underwent <sup>18</sup>F-FDG PET/CT imaging before chemotherapy, radiotherapy, and after interim chemotherapy, were retrospectively analyzed. Receive operating characteristic (ROC) curve analysis was performed to assess the predictive capacity of changes and change rates in PET/CT imaging parameters [maximum standardized uptake value (SUV<sub>max</sub>), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum tumor dissemination (D<sub>max</sub>)] for progression-free survival (PFS) and to identify optimal cutoff values. Kaplan-Meier survival curves were constructed, and the log-rank test was used to assess intergroup differences. Cox regression analysis was used to explore potential factors influencing PFS.</p><p><strong>Results: </strong>Among 86 patients [(45 men, 41 women, age: 57.8 ± 12.2 years)], the median PFS was 22.5 (14.5, 46) months. Until the last follow-up date, progression or recurrence occurred in 14 patients, while 9 patients died. The ROC curves indicated that the optimal cutoff values for predicting PFS were 99.10%, 99.72%, and 96.47% for ΔMTV%, ΔTLG%, and ΔD<sub>max</sub>%, respectively (area under the curve = 0.786-0.849, all P < 0.05). Cox univariate analysis demonstrated that the alteration rates in metabolic and diffusion parameters before and after treatment, including SUV<sub>max</sub>%, MTV%, TLG%, and D<sub>max</sub>%, were predictive of PFS (hazard ratio [HR] = 6.213-13.430, all P < 0.05). The Cox multivariate analysis demonstrated that ΔMTV% and ΔD<sub>max</sub>% independently predicted PFS, with HRs of 10.727 (95% confidence interval [CI] = 1.928-56.672, P = 0.007) and 7.178 (95%CI = 1.514-34.041, P = 0.013), respectively. We established a new prediction model by combining the ΔMTV% and ΔD<sub>max</sub>% parameters, and the results of the model showed statistically significant differences in PFS between the high, intermediate, and low-risk groups. The model predicted higher effects than individual indicators.</p><p><strong>Conclusion: </strong>The rate of change in metabolic and diffusion parameters on interim PET/CT can predict the prognosis of patients with DLBCL.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"411"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02126-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To investigate the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in interim therapeutic and prognostic evaluation of patients with diffuse large B-cell lymphoma (DLBCL).

Materials and methods: Data of 86 patients with pathologically confirmed DLBCL who underwent 18F-FDG PET/CT imaging before chemotherapy, radiotherapy, and after interim chemotherapy, were retrospectively analyzed. Receive operating characteristic (ROC) curve analysis was performed to assess the predictive capacity of changes and change rates in PET/CT imaging parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum tumor dissemination (Dmax)] for progression-free survival (PFS) and to identify optimal cutoff values. Kaplan-Meier survival curves were constructed, and the log-rank test was used to assess intergroup differences. Cox regression analysis was used to explore potential factors influencing PFS.

Results: Among 86 patients [(45 men, 41 women, age: 57.8 ± 12.2 years)], the median PFS was 22.5 (14.5, 46) months. Until the last follow-up date, progression or recurrence occurred in 14 patients, while 9 patients died. The ROC curves indicated that the optimal cutoff values for predicting PFS were 99.10%, 99.72%, and 96.47% for ΔMTV%, ΔTLG%, and ΔDmax%, respectively (area under the curve = 0.786-0.849, all P < 0.05). Cox univariate analysis demonstrated that the alteration rates in metabolic and diffusion parameters before and after treatment, including SUVmax%, MTV%, TLG%, and Dmax%, were predictive of PFS (hazard ratio [HR] = 6.213-13.430, all P < 0.05). The Cox multivariate analysis demonstrated that ΔMTV% and ΔDmax% independently predicted PFS, with HRs of 10.727 (95% confidence interval [CI] = 1.928-56.672, P = 0.007) and 7.178 (95%CI = 1.514-34.041, P = 0.013), respectively. We established a new prediction model by combining the ΔMTV% and ΔDmax% parameters, and the results of the model showed statistically significant differences in PFS between the high, intermediate, and low-risk groups. The model predicted higher effects than individual indicators.

Conclusion: The rate of change in metabolic and diffusion parameters on interim PET/CT can predict the prognosis of patients with DLBCL.

评价18F-FDG PET/CT对弥漫性大b细胞淋巴瘤中期疗效和预后的ΔMTV%、ΔDmax%和%ΔSUVmax。
目的:探讨18f -氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET/CT)在弥漫性大b细胞淋巴瘤(DLBCL)患者中期治疗和预后评估中的价值。材料与方法:回顾性分析86例经病理证实的DLBCL患者化疗前、放疗前及中期化疗后行18F-FDG PET/CT显像的资料。通过接受工作特征(ROC)曲线分析,评估PET/CT成像参数[最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)、病灶总糖酵解(TLG)和最大肿瘤播散(Dmax)]对无进展生存(PFS)的变化和变化率的预测能力,并确定最佳临界值。构建Kaplan-Meier生存曲线,采用log-rank检验评估组间差异。采用Cox回归分析探讨影响PFS的潜在因素。结果:86例患者[男45例,女41例,年龄:57.8±12.2岁],中位PFS为22.5(14.5,46)个月。截至最后随访日,14例患者出现进展或复发,9例患者死亡。ROC曲线显示,ΔMTV%、ΔTLG%和ΔDmax%预测PFS的最佳截止值分别为99.10%、99.72%和96.47%(曲线下面积= 0.786 ~ 0.849,所有P max%、MTV%、TLG%和Dmax%均可预测PFS,风险比[HR] = 6.213 ~ 13.430,所有P max%独立预测PFS,风险比分别为10.727(95%可信区间[CI] = 1.928 ~ 56.672, P = 0.007)和7.178(95%可信区间[CI] = 1.514 ~ 34.041, P = 0.013)。我们结合ΔMTV%和ΔDmax%参数建立了新的预测模型,模型结果显示高、中、低危组PFS差异有统计学意义。该模型预测的效果比单个指标更高。结论:中期PET/CT代谢和弥散参数变化率可预测DLBCL患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信